[86]
In Novopharm's submission, there was sufficient evidence before Prothonotary Milczynski for her to conclude that Novopharm's formulation and bioequivalence information were confidential and ought to be protected by the Protective Order. Certainly, she was not clearly wrong or acting on a misapprehension of the facts when she did so.
6. ANALYSIS
The Test